News
Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board
-- Dr. Ashworth Brings Decades of Scientific and Clinical Experience Translating Synthetic Lethality Discoveries into Precision CancerTherapies -- South San Francisco, Calif., – Mar. 24, 2026 (Read [...]
New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal
-- Study highlights importance of cancer driver biology in translating results from lab to patients ---- Findings validate proprietary OncoSLX Platform™, a pharmacogenetic approach that captures the [...]
Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research
Leapfrog Bio’s Precision PGx Platform™ discovered a clinically significant link between the EP300 gene and bromodomain and extra-terminal domain (BET) protein inhibitors Presentation describes the discovery, characterization, [...]
Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform™
Proof-of-concept retrospective analyses performed on currently marketed cancer drugs demonstrate the clinical relevance of Precision PGx Platform™ predictions Proprietary Precision PGx Platform™ rapidly discovers novel therapeutic options [...]